Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Emory University
With
Cephalon
This study is being conducted at two sites in the United States. Approximately 50 patients, who are between the ages of 18 and 65 years old will be enrolled at Emory. This study consists of two parts. The first part consists of 12 weeks of open-label treatment with Gabitril. If the study doctor determines that the patients condition has improved and they have completed the initial 12 weeks of treatment they may be eligible for the second part of the study. This part is a 24-week double-blind treatment period with either Gabitril or placebo (inactive medication). There will also be a follow-up visit about 1 to 3 weeks after they have completed taking the study medication. Altogether study participation is expected to last approximately 37 weeks.
Age
18–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Primary diagnosis of SAD
CGI (S) ≥ 4 at screen
LSAS ≥ 50 at baseline
Covi Anxiety Scale score greater than the Raskin depression Scale total score at screen
You may not be if
Non-responsive to adequate trials of two or more treatment medications, if previously treated for SAD.
HAM-D ≥15 or a score of \>2 on Item 1 at baseline
Serious or unstable medical condition
Alcohol or substance use disorder within 6 months prior to study
Clareo Health | Study To Evaluate The Effects Of Gabitril™ In Patients With Social Anxiety Disorder
